Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | CD38 | P28907 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5634316 | 0.80 | TSHR (0.40) | TSHRNPC1HSD17B10MAPK1MEN1 | |
| SCHEMBL16370253 | 0.69 | TSHR (0.72) | TSHRNPC1HSD17B10MAPK1MEN1 | |
| SCHEMBL14603059 | 0.63 | TSHR (0.39) | TSHRNPC1HSD17B10MAPK1KMT2A | |
| SCHEMBL5635644 | 0.63 | TSHR (0.39) | TSHRNPC1HSD17B10MAPK1KMT2A | |
| SCHEMBL13550020 | 0.61 | ABL1 (0.46) | MAPK1CYP1A2 | |
| SCHEMBL23572997 | 0.60 | HRH4 (0.47) | HSD17B10MAPK1CYP1A2HRH4LOXL2 | |
| SCHEMBL20815982 | 0.59 | CYP11B1 (0.57) | TSHRHSD17B10MAPK1KMT2ACYP1A2 | |
| SCHEMBL17250004 | 0.59 | CYP3A4 (0.50) | TSHRHSD17B10CYP1A2HRH4ALDH1A1 | |
| SCHEMBL18855229 | 0.59 | LOXL2 (0.37) | HSD17B10MAPK1CYP1A2HRH4CD38 | |
| SCHEMBL19185287 | 0.59 | LOXL2 (0.40) | TSHRHSD17B10MAPK1CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157580-B2 | Aminopyrimidine and aminopyridine anti-inflammation agents | ROCHE PALO ALTO LLC (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050107403-A1 | Aminopyrimidine and aminopyridine anti-inflammation agents | HAWLEY RONALD C (US) | 2005-05-19 | — | — | US | disclosed |
| US-6846828-B2 | Aminopyrimidine and aminopyridine anti-inflammation agents | ROCHE PALO ALTO LLC (US) | 2005-01-25 | — | — | US | disclosed |
| EP-1444223-A1 | AMINOPYRIMIDINES AND -PYRIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-11 | — | — | EP | disclosed |
| US-20030144303-A1 | Aminopyrimidine and aminopyridine anti-inflammation agents | SYNTEX (U.S.A.) LLC | 2003-07-31 | — | — | US | disclosed |
| WO-2003040131-A1 | AMINOPYRIMIDINES AND PYRIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107403-A1 | Aminopyrimidine and aminopyridine anti-inflammation agents | IL6, DPYD, TYMP | TSHR 4730/4885NPC1 4212/4885HSD17B10 3494/4885 |
| US-20030144303-A1 | Aminopyrimidine and aminopyridine anti-inflammation agents | IL6, DPYD, TYMP | TSHR 4733/4885NPC1 4028/4885HSD17B10 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.